Desoximetasone topical - Taro Pharmaceuticals

Drug Profile

Desoximetasone topical - Taro Pharmaceuticals

Alternative Names: Desoximetasone 0.25% or 0.5% topical spray - Taro Pharmaceuticals USA; Desoximetasone topical spray - Taro Pharmaceuticals; DSXS; Topicort

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medicis Pharmaceutical Corporation
  • Developer Taro Pharmaceuticals USA
  • Class Anti-inflammatories; Corticosteroids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Plaque psoriasis
  • Phase III Atopic dermatitis

Most Recent Events

  • 24 Jan 2017 The US FDA approves first generic equivalent available in USA for Plaque psoriasis
  • 01 Dec 2016 Taro Pharmaceuticals completes a phase III trial in Plaque psoriasis (In adolescents, In adults, In the elderly) in USA (NCT02932462)
  • 01 Aug 2016 Taro Pharmaceuticals initiates a phase II/III trial for Atopic dermatitis (In adolescents, In children, In infants) in USA (Topical) (NCT02932891)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top